Latest Working Capital News

Bio-Gene Technology Limited reported a net loss of AUD 2.58 million for FY2025 while making significant strides in developing its bio-insecticides Flavocide and Qcide, securing US Department of Defense grants and expanding global partnerships.

Austin Engineering reported a robust 22.2% revenue increase in FY25, driven by a strong North American expansion and improved margins in Asia Pacific. Despite some operational challenges in Chile, the company’s underlying profits soared, setting a confident tone for FY26.

SPC Global reports stronger-than-expected FY25 results driven by international growth and synergy gains, while unveiling a new premium beverage division and a major lender transition.

Viva Energy reported a statutory half-year loss of $195.4 million driven by significant retail site impairments and weak refining margins, yet underlying profit on a replacement cost basis remained positive at $62.6 million. The company declared a fully franked interim dividend of 2.83 cents per share, signaling confidence despite operational headwinds.

Australian Clinical Labs delivered solid FY25 financial results with revenue up 6.4% and EBIT rising 8.7%, underpinned by operational efficiencies and strategic innovation. The company’s FY26 guidance signals continued growth amid evolving market conditions and government fee pressures.

Felix Group Holdings has launched a $1 million Share Purchase Plan offering shares at a 3.7% discount to support its acquisition of Nexvia Pty Ltd and growth initiatives.

Veris Limited has reported a significant turnaround in FY25, posting a $2 million profit before tax on $97.2 million revenue, driven by growth in digital and spatial advisory services and strategic acquisitions.

Veris Limited has returned to profitability in FY25, driven by strong growth in its digital and spatial advisory services, while declaring its first dividend in years and strengthening its cash position.

Imricor Medical Systems reported a sharp 52% revenue decline and a 92% increase in net loss for H1 2025, offset by a $42.8 million equity raise boosting liquidity. The company is investing heavily in European sales and clinical trials while pursuing FDA approval.

K&S Corporation reported a 9% decline in underlying profit before tax for FY2025, alongside a 9.7% drop in revenue, as it invests heavily in property and terminal upgrades while navigating safety regulatory pressures.

Ambertech Limited reported a 6% increase in revenue to $101.2 million for FY25, yet net profit after tax fell sharply by 38% to $0.84 million amid inflationary pressures and increased costs. The company declared a fully franked final dividend and remains optimistic about FY26.

Vital Metals Limited has had its trading suspension lifted following announcements addressing an ASX Price and Volume Query and a new capital raise, signaling renewed market activity.